Search Results - "Nicolás de Prado, I"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    P735 Immunogenicity differences between anti-TNF drugs by Gómez Espín, R M, Nicolás de Prado, I, Iniesta Navalón, C, Rentero Redondo, L, Gil Candel, M, Martínez Crespo, J J

    Published in Journal of Crohn's and colitis (25-01-2019)
    “…Abstract Background The aim of this study was to determine the prevalence of immunogenicity in patients receiving anti-TNF drugs (infliximab and adalimumab) in…”
    Get full text
    Journal Article
  2. 2

    P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease by Nicolás de Prado, M I, Iniesta Navalón, C, Gomez Espin, R, Gil Candel, M, Serrano Díaz, L, Rentero Redondo, L, Martinez Crespo, J J

    Published in Journal of Crohn's and colitis (15-01-2020)
    “…Abstract Background Ustekinumab (UTK) is a human immunoglobulin (Ig) G1 kappa monoclonal antibody approved in 2017 for the treatment of Crohn’s Disease (CD)…”
    Get full text
    Journal Article
  3. 3

    Vascular complications of pancreatitis by Nicolás de Prado, I, Corral de la Calle, M A, Nicolás de Prado, J M, Gallardo Sánchez, F, Medranda, M A

    Published in Revista clínica espanõla (01-07-2005)
    “…Vascular complications of pancreatitis are infrequent but important clinical problems because of their higher mortality. Pseudocysts that appear in 5%-50%…”
    Get more information
    Journal Article
  4. 4

    Idiopathic cholestasis associated with bloody diarrhea as the first manifestation of Hodgkin's lymphoma by Rodríguez-Gil, F J, Rincón-Fuentes, J P, García-Pérez, B, Conesa-Pallarés, F J, Vicente-López, J J, Grau-García, F J, Martínez-García, P, Nicolás de Prado, I, Morán-Sánchez, S

    Published in Gastroenterología y hepatología (01-04-2006)
    “…Jaundice in Hodgkin's disease occurs in 3-13% of the cases reported in the medical literature and can be due to several causes. Cholestatic jaundice associated…”
    Get more information
    Journal Article
  5. 5

    Amebic colitis in an immunocompetent host by Morán Sánchez, S, Baños Madrid, R, Gallardo Sánchez, F, Nicolás De Prado, I, Serrano Jiménez, A

    “…Amebic colitis is a low prevalence illness in developed countries. Its diagnosis is infrequent and is usually made in certain groups of risk. Images studies…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Colitis amebiana en paciente inmunocompetente by Morán Sánchez, S., Baños Madrid, R., Gallardo Sánchez, F., Nicolás de Prado, I., Serrano Jiménez, A.

    “…La colitis amebiana es una entidad de baja prevalencia en el mundo occidental. Su diagnóstico es infrecuente y se halla restringido a ciertos grupos de riesgo…”
    Get full text
    Journal Article
  8. 8